Preferred Label : oligonucleotides;

MeSH definition : Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed);

MeSH synonym : Oligonucleotide;

MeSH annotation : 2-12 nucleotides;

Wikipedia link : https://en.wikipedia.org/wiki/Oligonucleotide;

Is substance : O;

Details


Main resources

You can consult :

Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)

https://ansm.sante.fr/tableau-marr/inotersen
2024
false
false
false
France
French
risk management
Inotersen
inotersen
Drug-Related side effects and adverse reactions
patients guideline
drug information
eye diseases
glomerulonephritis
thrombocytopenia
oligonucleotides
oligodeoxyribonucleotides, antisense

---
https://www.has-sante.fr/jcms/p_3199401/fr/spinraza
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
child
infant
insurance, health, reimbursement
injections, spinal
nusinersen
nusinersen
muscular atrophy, spinal
5q spinal muscular atrophy
oligonucleotides

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/recommandations-sur-les-informations-requises-au-suivi-de-lusage-du-nusinersen-en-contexte-de-vie-reelle.html
2020
false
false
false
Canada
guideline
life
nusinersen
guideline adherence
oligonucleotides

---
https://www.has-sante.fr/portail/jcms/c_2965636/fr/tegsedi
2019
false
true
false
false
France
French
treatment outcome
orphan drug production
amyloidosis, hereditary, Transthyretin-Related
injections, subcutaneous
oligonucleotides, antisense
adult
aged
evaluation of the transparency committee
polyneuropathies
inotersen
amyloid neuropathies, familial
Inotersen
oligonucleotides

---
https://www.has-sante.fr/jcms/p_3106176/fr/tegsedi
2019
false
false
false
France
inotersen
Inotersen
evaluation of the transparency committee
Inotersen
oligonucleotides

---
https://www.has-sante.fr/jcms/c_2965636/fr/tegsedi
2019
false
false
false
France
oligonucleotides
adult
polyneuropathies
injections, subcutaneous
amyloidosis, hereditary, Transthyretin-Related
oligodeoxyribonucleotides, antisense
orphan drug production
treatment outcome
evaluation of the transparency committee
amyloid neuropathies, familial

---
https://www.ema.europa.eu/en/medicines/human/EPAR/waylivra
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Volanesorsen
Volanesorsen
orphan drug production
familial hyperchylomicronemia syndrome
injections, subcutaneous
apolipoprotein c-iii
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
volanesorsen
ISIS 304801
ISIS 304801
hyperlipoproteinemia type i
oligonucleotides
oligonucleotides

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=44554
2019
false
false
false
France
insurance, health, reimbursement
nusinersen
muscular atrophy, spinal
orphan drug production
muscular atrophy, spinal
legislation
oligonucleotides

---
https://ansm.sante.fr/informations-de-securite/spinraza-nusinersen-v-information-sur-le-risque-dhydrocephalie-communicante-non-reliee-a-une-meningite-ou-a-une-hemorragie
2018
false
false
false
France
French
pharmacovigilance note
injections, spinal
nusinersen
nusinersen
communicating hydrocephalus
adult
child
signs and symptoms
communicating hydrocephalus
risk
continuity of patient care
muscular atrophy, spinal
drug monitoring
information dissemination
product surveillance, postmarketing
hydrocephalus
hydrocephalus
oligonucleotides

---
https://www.has-sante.fr/portail/jcms/c_2826600/fr/spinraza
https://www.has-sante.fr/portail/jcms/c_2826600/fr/spinraza-nusinersen-oligonucleotide-antisens
2018
false
false
false
France
French
treatment outcome
orphan drug production
oligonucleotides
spinal muscular atrophies of childhood
injections, spinal
survival of motor neuron 1 protein
survival of motor neuron 2 protein
genetic diseases, inborn
spinal muscular atrophies of childhood
child
infant
chromosomes, human, pair 5
nusinersen
evaluation of the transparency committee
nusinersen
guidelines for drug use

---
https://www.ema.europa.eu/medicines/human/EPAR/Tegsedi
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
amyloidosis, hereditary, Transthyretin-Related
injections, subcutaneous
continuity of patient care
oligonucleotides, antisense
oligonucleotides, antisense
amyloid neuropathies
drug interactions
pregnancy
adult
aged
drug evaluation, preclinical
inotersen
polyneuropathies
amyloid neuropathies, familial
Inotersen
Inotersen
oligonucleotides
oligonucleotides

---
https://www.ema.europa.eu/medicines/human/EPAR/Spinraza
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
orphan drug production
oligonucleotides
oligonucleotides
product surveillance, postmarketing
spinal muscular atrophies of childhood
injections, spinal
survival of motor neuron 1 protein
survival of motor neuron 2 protein
genetic diseases, inborn
spinal muscular atrophies of childhood
child
infant
drug evaluation, preclinical
chromosomes, human, pair 5
nusinersen
nusinersen
nusinersen

---
Nous contacter.
19/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.